A 2011 study by Fujie Zhang et al suggested that initiating highly active antiretroviral therapy in patients with higher CD4 counts could potentially reduce treatment expenses related to opportunistic infections in immunocompromised individuals [16]. This evidence concerns the gene CD4 and Opportunistic infection.